Adimmune Corporation operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Adimmune with three other
companies in this sector in Taiwan:
Abnova (Taiwan) Corporation
sales of 426.02 million Taiwanese Dollars [US$13.88 million]
of which 27%
was Monoclonal Antibodies),
(770.61 million Taiwanese Dollars [US$25.11 million]
Syn-Tech Chem. & Pharm. Co., Ltd.
(784.83 million Taiwanese Dollars [US$25.57 million]
of which 99%
was Sales revenue).
Adimmune reported sales of 822.37 million Taiwanese Dollars (US$26.79 million)
December of 2018.
increase of 46.1%
versus 2017, when the company's sales were 562.74 million Taiwanese Dollars.
Sales of Finished Products Sales saw an increase
47.3% in 2018, from
556.82 million Taiwanese Dollars to 820.03 million Taiwanese Dollars.
Not all segments of Adimmune experienced an increase in sales in 2018:
sales of Semi Finished Products Sales fell 67.3% to 1.61 million Taiwanese Dollars.
(However, this segment's sales were only a very small portion of the company's overall sales).
Adimmune also experienced decreases in sales in
Others Income (down 27.7% to 733,000.00 Taiwanese Dollars)